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SUMMARY OF CONTENT  
 
In this MPH dissertation, comprising three parts, a systematic review on prevalence of XDR-
TB, and factors associated with the prevalence of XDR-TB in Africa was performed.   
Part A outlines the research protocol and provides a brief background to the research topic and 
the process of this systematic review.  
Part B provides extensive literature that is relevant to the prevalence of and factors associated 
with XDR-TB in Africa.  
Part C details the results and discussion of this systematic review. The part is written in a format 
of journal manuscript ready to publish in the PLOS journal.  
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PART A: PROTOCOL 
 
List of abbreviations 
DST - Drug Susceptibility Test 
DS-TB – Drug Susceptible Tuberculosis 
DR-TB – Drug-resistant Tuberculosis 
HIV – Human Immunodeficiency Virus 
MDR-TB – Multi Drug-resistant Tuberculosis 
MESH – Medical Subject Headings  
TB - Tuberculosis 
WHO - World Health Organization 
XDR-TB – Extensively Drug-resistant Tuberculosis 
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Operational definitions 
Children- refers to individuals who are <15 years of age (based on WHO criteria).  
Factors associated with the prevalence of XDR-TB - any variable that is associated with the 
likelihood of a diagnosis with XDR-TB. 
MDR-TB - disease caused by Mycobacterium tuberculosis with resistance to isoniazid and 
rifampicin, with or without resistance to other first-line drugs (FLD). 
Prevalence – for this review, prevalence will refer to the proportion of XDR-TB cases reported 
in studies from January 2006 to May 2018. 
Pre-XDR-TB – disease caused by Mycobacterium tuberculosis with resistance to isoniazid 
and rifampicin, and either a fluoroquinolone or second-line injectable drug, but not both.   
Pulmonary tuberculosis - refers to any bacteriologically confirmed case of TB involving the 
lung parenchyma or the tracheobronchial tree. 
XDR-TB – defined as a disease caused by Mycobacterium tuberculosis with resistance to at 
least isoniazid and rifampicin, any fluoroquinolone, and at least one of three injectable anti-TB 
treatment drugs (amikacin, capreomycin, or kanamycin). 
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1. BACKGROUND  
Drug-resistant tuberculosis (DR-TB) continues to be a global public health burden. In 2016 the 
World Health Organization (WHO) estimated a global incidence of 600 000 drug-resistant TB 
cases, and extensively drug-resistant TB (XDR-TB) constituted 9.6% of the reported DR-TB 
cases (1). XDR-TB is defined as a disease caused by Mycobacterium tuberculosis with 
resistance to at least isoniazid and rifampicin, any fluoroquinolone, and at least one of three 
injectable anti- tuberculosis drugs (amikacin, capreomycin, or kanamycin) (2). To date, 123 
countries have reported at least one case of XDR-TB compared to 92 in 2012, and 55 in 2008 
respectively (3–5). Africa accounts for 13.6% of the global XDR-TB cases, with South Africa 
reporting the highest number (967 out of 1092) of those XDR-TB cases (1). 
 
Available data on the prevalence of XDR-TB in Africa is limited. Although several studies (6–
14) have been conducted in multiple settings in Africa to determine the prevalence of  DR-TB, 
none of these studies reference XDR-TB. The reason why some of these studies could not 
identify XDR-TB is because drug susceptibility testing (DST) focused on first-line anti-
tuberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) (6–8,14). A few 
studies have reported prevalence of  XDR-TB as 5.9% in Burkina Faso (15), 4.9% in South 
Africa (16), while Lesotho and Mali respectively only reported XDR-TB cases but not the 
prevalence of XDR-TB (17,18). The true prevalence of XDR-TB in Africa is thus unknown as 
data on the prevalence of XDR-TB has not been systematically reviewed to establish the true 
burden of XDR-TB in Africa. 
 
Multiple factors have been reported to influence the prevalence of XDR-TB. The lack of 
laboratory capacity to conduct DST to diagnose XDR-TB result in subsequent under diagnosis 
of XDR-TB (1). The unavailability of a rapid molecular diagnostic test for XDR-TB further 
11 
 
contributes to delayed and underdiagnosis of XDR-TB (19). Poor infection control in 
healthcare facilities has also been suspected of contributing to the spread of XDR-TB 
(18,20,21).  
 
XDR-TB can develop during TB treatment (acquired) or from infection by an XDR-TB strain 
(primary resistance) (22). The practice of discharging patients who failed XDR-TB treatment 
back into the community poses a threat of primary transmission of XDR-TB in the community 
(23). This could potentially increase the prevalence of XDR-TB, by means of the transmission 
of XDR-TB from programmatically incurable patients to their contacts (23).  
 
Favourable outcomes are reported for those patients who used new generation anti-tuberculosis 
drugs, such as bedaquiline, in the management of XDR-TB (24). Treatment with new 
generation anti-tuberculosis drugs thus have great potential to prevent primary transmission of 
XDR-TB as a result of increased cure rate (24). The successful management of XDR-TB cases 
suggests that primary transmission of XDR-TB to contacts is preventable and consequently 
reducing the prevalence of DR-TB.  
 
Several factors have been reported to be associated with the likelihood of XDR-TB in Africa. 
These factors include, but might not be limited to; age, sex, HIV status, history of previous TB 
treatment, hospitalization history, CD4 count, weight, smoking status and  diabetes 
(20,23,25,26). These factors are typically reported as characteristics of patients diagnosed with 
XDR-TB and not as factors associated with the likelihood of a diagnosis with XDR-TB (25).  
According to the only study that explicitly focused on XDR-TB predictive factors HIV status, 
history of previous TB treatment (treatment failure), and history of hospitalization for more 
than 14 days are independent factors associated with the diagnosis of XDR-TB (25).  
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Conducting a systematic review and meta-analysis will enable us to establish the prevalence of 
XDR-TB, and factors associated with the XDR-TB prevalence, in Africa. Furthermore, such 
knowledge will assist in identifying populations at substantial risk of being diagnosed with 
XDR-TB and guide appropriate XDR-TB intervention strategies including healthcare policies. 
 
1.1. Problem statement  
To date, there have been no published systematic review and or meta-analysis conducted on 
the prevalence of XDR-TB in Africa. Systematic reviews and meta-analysis on the prevalence 
of multi drug-resistant tuberculosis (MDR-TB) rather than XDR-TB are however reported 
(27,28). Furthermore, the only meta-analysis reported regarding Africa focused on the factors 
associated with MDR-TB in Africa (29). In 2017, the WHO reported a decrease in the rate of 
drug-susceptible tuberculosis (DS-TB) cases yet the prevalence rate of XDR-TB continue to 
increase (1). Prevalence rates are central to healthcare policy planning and hence the need to 
ascertain the prevalence rate of XDR-TB in Africa.  Likewise, a meta-analysis of factors 
associated with the prevalence of XDR-TB in Africa will allow us to ascertain and assess the 
strength of association between factors associated with XDR-TB prevalence in an African 
context. The knowledge gained will not only further existing academic and professional 
knowledge related to XDR-TB but will similarly enhance clinical management.  
 
1.2.Justification and Implications of this review 
The dearth of African focused systematic reviews and meta-analysis related to prevalence, and 
factors associated with the prevalence of XDR-TB, emphasizes such demand. An African 
focused systematic review, and meta-analysis, will enable the synthesis of evidence and 
contribute to professional and academic knowledge on the prevalence and factors associated 
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with the prevalence of XDR-TB in Africa, ultimately benefitting patients and communities in 
Africa. Furthermore, findings related to an African focused systematic review and meta-
analyses have the potential to inform healthcare policy and subsequent healthcare service 
planning. Results could be used in mathematical disease models to estimate the lifetime 
prevalence of XDR-TB in Africa.  Moreover, the results of this review have potential to provide 
valuable information related to factors associated with the prevalence XDR-TB in Africa with 
ultimate impact on TB healthcare service delivery. 
 
1.3. Research question  
What is the prevalence of, and factors associated with the prevalence of XDR-TB in Africa?  
2. OBJECTIVES OF THE STUDY 
2.1 Primary objective 
• To assess the prevalence of XDR-TB amongst participants tested for second-line anti-
tuberculosis drug resistance in Africa. 
2.2. Secondary objectives 
• To assess the prevalence of XDR-TB amongst participants with resistance to at least 
one anti-TB drug 
• To assess the prevalence of XDR-TB amongst participants with MDR-TB 
• To assess the prevalence of XDR-TB amongst patients with resistance to at least one 
second-line anti-TB drug 
• To assess the factors associated with the prevalence of XDR-TB in Africa. 
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3. METHODS  
3.1. Criteria for considering studies for this review  
3.1.1. Types of studies 
For the assessment of XDR-TB prevalence observational studies, population-based studies, 
cross-sectional studies and cross-sectional surveys will be considered. Baseline data of cohort 
studies, cases control studies and experimental studies that report on the prevalence of XDR-
TB among the study population will also be considered. Prevalence data will not be extracted 
from studies with an exclusive XDR-TB study population.  For the assessment of factors 
associated with the prevalence of XDR-TB in Africa observational studies, population-based 
studies, cross-sectional studies and cross-sectional surveys will be considered. Baseline data of 
cohort studies (both retrospective and prospective), case control studies and experimental 
studies that report on the prevalence of XDR-TB among the study population data will be 
considered. 
 
3.1.2. Types of participants 
 
This review will include studies reporting laboratory confirmed pulmonary XDR-TB in adults 
(15 years and older), irrespective of gender and socio-economic backgrounds. Studies reporting 
patients suspected to have TB will also be included. Studies will be eligible for inclusion if 
XDR-TB diagnosis was reported as based on any of the WHO recommended laboratory 
procedures for first-line and second-line anti-tuberculosis drug resistance testing   (30,31). 
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3.1.3.  Study setting 
 
This review will include studies conducted in Africa.  The following countries will be included: 
Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central 
African Republic, Chad, Comoros, Congo (Brazzaville), Congo (Democratic Republic), Cote 
d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon,  Gambia, Ghana, 
Guinea, Guinea- Bissau, Kenya, Lesotho, Libya, Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Reunion, Rwanda, 
Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, 
South Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, and 
Zimbabwe (Appendix 1).  
 
3.1.4. Types of outcome measures 
• XDR-TB - as determined by WHO recommended laboratory diagnostic tests (30,31) 
• DR-TB - refers to Mtb that is resistance to at least one anti-TB drug  
• MDR-TB – refers to Mtb that is resistant to both isoniazid and rifampicin. 
• Second-line resistance - refers to Mtb that is resistant to at least one second-line anti-
TB drug  
 
3.1.5. Exclusion criteria 
The following studies will be excluded: 
• XDR-TB prevalence is not explicitly reported (e.g. where results are inextricable 
including other types of DR-TB cases). 
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• Studies exclusively including children. Studies reporting results related to adults and 
children will be included provided results clearly differentiate between the 
prevalence, and factors associated with prevalence regarding children. 
• Generic definition for XDR-TB not applied.  
• Duplicate publications. The most recent report will be included when duplicate 
publications are encountered.  
• Review studies (narratives, expert opinions).  
• Studies that only include people living with HIV. 
• Studies that lacks clear research methodology. 
• Studies conducted with no ethical approval or clearance.  
• Studies that only analyse laboratory specimens/results without enrolling any patients. 
• Publications in languages other than in English. 
• Studies that report on the evaluation and comparison of TB diagnostic tests. 
 
3.2. Search methods for identification of studies  
Published and unpublished literature will be comprehensively searched to identify relevant 
articles. A search strategy will be developed in MEDLINE, including both the medical subject 
headings (MESH) and free text (Appendix 2).  Assistance from a librarian will be sought to 
help design an appropriate search strategy for this review. The search strategy will be adapted 
to various electronic databases using applicable vocabulary. A reference software programme 
(EndNote) will be used to manage study articles. 
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3.3. Electronic searches 
Relevant articles will be sought and identified from electronic databases such as PubMed/ 
Medline, CINAHL, Scopus, Web of Science, ScieELO, PyschInfo, Cochrane Central Register 
of Controlled Trials (Central), (Africa-wide) allied health, Health Source: Academic Edition 
and Google Scholar. A search for XDR-TB prevalence data, and factors associated with the 
prevalence of XDR-TB will be performed regarding state health surveys of countries included 
in this review and meta-analysis.  
Reference lists of the articles obtained from electronic data bases will be interrogated to 
identify articles missed during the electronic databases searches.  Additionally, grey literature 
such as conference papers will be explored. 
 
3.4. Data collection  
3.4.1. Selection of studies  
 
Step 1: One reviewer will scan relevant articles for possible eligibility. Articles will be 
excluded based on their titles.  
Step 2: Two reviewers will then read titles and abstracts of all initially include articles to 
determine eligibility for inclusion in the study.  
Step 3: Full texts of articles deemed eligible will be obtained and reviewed independently by 
the two reviewers. 
A third reviewer will be consulted in the event that reviewers have a disagreement on exclusion 
or inclusion of an article during initial review process. A summary table will be compiled 
detailing reason for exclusion of documented studies.  
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3.4.2. Data extraction and management  
 
Data from full text of eligible articles will be independently extracted by two reviewers using 
a standardised data extraction form (Appendix 3). The data extraction form will be piloted on 
at least 5 of studies randomly selected from the included studies.   
Study characteristics such as country of study, study design, sample size, outcome measures, 
study population, study findings, and diagnostic criteria will be recorded. Each study will only 
contribute one estimate of an outcome measure and/or variable of interest. In the event that an 
individual study has multiple estimates of a single outcome measure of a variable of interest, 
only one estimate of each outcome variable will be selected to contribute to this review’s 
pooled estimate of each study outcome of interest. If the two reviewers disagree regarding data 
extracted a third reviewer will act as a mediator. 
 
3.5. Data analysis and synthesis 
 
The PRISMAS 2009 guidelines will be used to report the study findings (32) (Appendix 4). 
Data analysis will be done in two phases. The first phase of analysis will be to calculate the 
pooled prevalence rate estimates from the included studies. An application of random effect, 
and / or fixed effect method, will be applied depending on the heterogeneity of the included 
prevalence study estimates. The prevalence of XDR-TB will be pooled together by method of 
meta-analysis using REVMAN and or the statistical software STATA (33).  
The second phase will entail the synthesis of evidence relating to the second objective of this 
study. Factors associated with the prevalence of XDR-TB will be synthesised descriptively to 
understand individual factors associated with the prevalence of XDR-TB. The STATA, and or 
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REVMAN, statistical software will be used to pool together measurement outcomes of factors 
associated with the prevalence of XDR-TB.  
 
3.5.1. Assessment of risk of bias of included studies  
 
The quality of included studies will be assessed using various assessment tools. Observational 
studies will be assessed using the quality assessment tool developed by Hoy et al. 2012, and 
modified by Werfali et al. 2014 (34,35).  This prevalence study quality appraisal tool 
categorises studies into three groups; 0-5 points as high-risk studies, 6-8 points as moderate 
risk studies, and >8 as low risk studies (Table 1). The Newcastle-Ottawa appraisal tool will be 
used to appraise both cohort and case-control studies  (36,37). 
Two reviewers will independently assess the quality of all included studies followed by the 
comparison of their quality appraisal scripts. Disagreement on the quality scores will be 
resolved by unanimity between the two reviewers. Failure to reach a consensus will be 
mediated by a third reviewer.  Moreover, a funnel plot, if more than 10 studies included in the 
review, will be plotted to assess reporting bias of included studies. 
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Table 1: Assessment criteria for prevalence studies  
Items Quality score  
External validity  
 
1. Was the study’s target population a close representation of the national population in 
relation to relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target population? (1 point) 
3. Was some form of random selection used to select the sample, OR was a census 
undertaken? 
(1 point) 
4. Was the likelihood of non-response bias minimal? (1 point) 
 Total (4 points) 
Internal validity  
 
1. Were data collected directly from the participants (as opposed to a proxy)? (1 point) 
2. Was an acceptable case definition used in the study? (1 point) 
3. Was the study instrument that measured the parameter of interest shown to have validity 
and reliability? 
(1 point) 
4. Was the same mode of data collection used for all participants? (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest 
appropriate? 
(1 point) 
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point) 
 Total (6 points)  
*Quality assessment tool as developed Hoy et al. (34) and modified by Werfali et al. 2014 
(35). 
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3.5.2. Assessment of heterogeneity  
 
The results of studies to be included in this review and meta-analysis are expected to vary hence 
the need to determine the statistical heterogeneity. Statistical heterogeneity of the included 
studies will be evaluated using the Chi-squared test of homogeneity. Chi-squared results will 
be considered statistically significant at alpha level 0.10 (38). Statistical heterogeneity will 
further be assessed using the I2statistic to assess the degree of variation among the included 
studies. The I2 squared statistic results will be reported as a percentage (38). 
 
3.5.3. Dealing with missing data  
 
Missing, and unreported data from study articles will be sought from the corresponding author 
of published articles.  XDR-TB prevalence, and factors associated with the prevalence of XDR-
TB, will be calculated from study articles that report unweighted data but have reported 
numerator and denominator relating to XDR-TB. 
 
3.5.4. Subgroup and sensitivity analysis  
 
Subgroup analysis will be conducted were plausible. Potential sources of heterogeneity will be 
examined by conducting sensitivity analysis. Sensitivity analysis will also be carried out to 
determine whether the pooled measures of effect change when only high-quality studies are 
considered. Sensitivity analysis will also be conducted to determine the effect on the pooled 
measures of effect when the studies that contribute the largest weight to the pooled effected are 
temporarily excluded.  The chi-squared test for subgroup differences will be used to evaluate 
subgroup interactions. 
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3.5.5. Grading the quality of evidence  
The quality of evidence will be assessed using the GRADE approach (39).  
4. ETHICS 
The researcher plans to use only data and or study articles that are available in the public 
domain hence participants consent, and ethical clearance will not be required (40). However, 
exemption for ethical clearance of this protocol will be sought from the Faculty of Health 
Sciences Human Research Ethics Committee, University of Cape Town, South Africa.  
5. FUNDING  
No funding is expected for this review.  
6. DISSEMINATION  
The findings of this study will be distributed through peer reviewed publications and 
conference presentations. 
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1. Introduction  
PubMed and Google Scholar searches were conducted regarding articles to include in the 
literature review. Key words such as prevalence, epidemiology, risk factors, extensively drug-
resistant tuberculosis, drug-resistant tuberculosis, Africa, sub-Saharan Africa were used during 
the search. The search was not restricted to Humans and was done without any language 
restrictions. The aim of this literature review was to further an understanding of the prevalence 
of, and factors associate with, extensively drug-resistant tuberculosis (XDR-TB) in Africa. 
 
2. Epidemiology of DR-TB  
Drug-resistant tuberculosis (DR-TB), irrespective of the variety of different types of resistant 
profiles, is a global public health problem particularly in Africa (1).  Extensively drug-resistant 
tuberculosis (XDR-TB) in particular is defined  “Mycobacterium tuberculosis  with resistance 
to at least isoniazid, rifampicin, any fluoroquinolone and any of the anti-tuberculosis injectable 
drugs (amikacin, capreomycin, and kanamycin)” (2).   
 
DR-TB infection can either occur via primary or acquired transmission. Primary transmission 
occurs when the patients develops DR-TB by being infected with a drug-resistant strain. 
Acquired DR-TB occurs when a patient develops DR-TB during TB treatment (3,4). A 
particular mode of DR-TB mode of transmission (primary or acquired) can be confirmed 
through whole genome sequencing (5). 
 
DR-TB can be transmitted through various transmission routes including community 
transmission, nosocomial transmission, inadequate treatment and contact with an infectious 
DR-TB patient (6). Previously inadequate XDR-TB treatment has been thought to be the major 
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risk factor to develop XDR-TB because most of the patients diagnosed with XDR-TB had a 
history of previous TB treatment (7). However, emerging evidence suggests that most XDR-
TB infection could possibly be a result of primary transmission rather than infection from 
inadequate treatment (3). This implies that there is evidence to support the notion that XDR-
TB could be a result of primary transmission.   
 
DR-TB can be diagnosed through rapid testing. The GeneXpert MTB/ RIF diagnostic test is 
recommended by WHO as the diagnostic test for DR-TB (1). Resistance to rifampicin is used 
as indicator for multi drug-resistant tuberculosis (MDR-TB) (8). However, it is worth noting 
that there is no gold standard for evaluating drug resistance against anti-tuberculosis drugs (6).  
Patients thus testing as resistant to rifampicin should be subjected to further drug resistance 
testing to determine resistance to additional anti-tuberculosis drugs. Evaluation for extra drug 
resistance, against additional first and second-line anti-tuberculosis drugs in an attempt to 
diagnose DR-TB, can be done using tests such as a genotypic test called MTBDRplus (9).  
 
Rapid diagnosis of DR-TB is significant in the control and prevention of TB  (10). This is 
important because early diagnosis means that patients can be initiated on treatment, potentially 
preventing the spread of DR-TB (11). Adequate XDR-TB management entailing early 
diagnosis and treatment with the correct regimen is essential to preventing the transmission of 
XDR-TB (12) 
 
Additional measures to prevent DR-TB include infection control, and adequate treatment for 
DR-TB cases. Currently there is no vaccine for the prevention of TB infection in adults. The 
existing TB vaccine (Bacille Calmette-Guerin) prevents severe forms of TB in children (1). 
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Thus a vaccine with a high efficacy rate is needed in order to help prevent the infection of TB 
in adults (13). 
3. The burden of DR-TB 
3.1. The global burden of DR-TB   
The burden of tuberculosis remains high (1). In 2016, 123 countries reported at least one case 
of XDR-TB (1). Amongst the countries that recorded DR-TB cases, 91 countries stated the 
proportion of MDR-TB cases infected with XDR-TB (1).  
 
Globally, at the end of 2016, the proportion of XDR-TB cases among MDR-TB cases was 6.2 
% (95%CI 3.6-9.5%). In 2016 the proportion of XDR-TB was lower compared to previous 
years reported as  9.5%, 9.7%  and 9.0% in 2015, 2014 and 2013 respectively (1). This indicates 
a slight decrease in the global burden of XDR-TB which could be attributed to early detection 
of MDR through increased diagnostic testing.  
 
Globally, 600 000 new cases of rifampicin resistant tuberculosis (RR-TB) were detected in 
2016, while 82% (490 000) of these cases had MDR-TB (1).  The global incidence of MDR-
TB/RR-TB is estimated to be 4.1% while this burden varies across WHO regions (1). The 
WHO Europe region has the highest MDR-TB/RR-TB burden at 19% compared to other 
regions; Africa 2.7%, South East-Asia 2.8%, the Americas 2.9%, Eastern Mediterranean 
4.2% and Western pacific 5.3% (1). It is worth noting that WHO regions with a high 
incidence burden of MDR-TB/RR-TB also have a high incidence of MDR-TB/RR-TB among 
patients with a history of previous TB treatment (1).  This suggests that most of the patients 
with DR-TB develop DR-TB while on treatment or they represent DR-TB cases that relapsed. 
 
30 
 
3.2. The burden of DR-TB in Africa 
WHO defined three new TB High Burden Countries (HBC) categories, applicable globally to 
the period 2016 to 2020, namely: 1) TB HBC, 2) TB/HIV HBC and 3) MDR-TB HBC (1). 
Countries overlapping in all three categories could be considered as having a triple burden of 
TB disease. The MDR-TB category  includes XDR-TB given that XDR-TB cases are mostly 
reported as part of the MDR-TB data (1). Globally 48 countries are categorised as HBC of 
which more than 50% (25/48) are in Africa (Figure 1). 
 
Nine countries in Africa are categorised as MDR-TB HBC (Figure 1) of  which 8, Angola,  DR 
Congo, Ethiopia, Kenya, Mozambique, Nigeria and South Africa fall into the triple burden 
category (1). Somalia however, although considered a MDR-TB high burden country does not 
fall into the TB HBC category (Figure 1). 
 
Globally 14 countries fall into the triple burden HBC category. In Africa, Angola, Democratic 
Republic of Congo, Ethiopia, Kenya, Mozambique, Nigeria, South Africa and Zimbabwe are 
listed in this category,  
 
A total of 1092 XDR-TB cases were notified from the African region  amongst the 8014 XDR-
TB cases reported globally in 2016(1). WHO estimates the MDR-TB/RR-TB incidence among 
the 30 MDR-TB HBC in Sub-Sahara as; Mozambique 3.7%, Nigeria 4.3%, Somalia 8.7% and 
South Africa 3.4%.  Furthermore, there is a high incidence of MDR-TB/RR-TB  among patients 
with a history of previous tuberculosis treatment in African countries like Somalia 47%, 
Nigeria 25% (1).  
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Figure 1: Countries as categorised into the three HBC categories being used by during 
the period 2016-2020 (1). 
 
3.3. Prevalence of DR-TB in Africa 
 
Available data regarding the prevalence of XDR-TB in Africa is limited. Albeit several studies 
(14–22) have been conducted in multiple settings in Africa to determine the prevalence of  DR-
TB, none of these studies reference XDR-TB. The reason why some of these studies could not 
identify XDR-TB is because drug susceptibility testing (DST) focused on first-line anti-
tuberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) (14–16,22). A few 
studies have reported prevalence of XDR-TB as 5.9% in Burkina Faso (23), 4.9% in South 
Africa (24), while Lesotho and Mali respectively only reported XDR-TB cases but not the 
prevalence of XDR-TB (25,26). The true prevalence of XDR-TB in Africa is thus unknown as 
data on the prevalence of XDR-TB has not been systematically reviewed to establish the true 
burden of XDR-TB in Africa. 
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From 2006 to 2016, only 12 out of 54 countries in Sub-Saharan African have completed 
national TB prevalence surveys (1). These countries include Ethiopia, Nigeria, Gambia, 
Rwanda, United Republic of Tanzania, Malawi, Ghana, Sudan, Zambia, Zimbabwe, Kenya, 
and Uganda (1). This illustrates why there is limited data on the prevalence of XDR-TB in 
Africa. It is thus crucial for more countries in Africa to conduct prevalence surveys as this 
would provide data on the level of drug-resistance in Africa. Moreover, some research 
publications only report on MDR-TB and do no further stratify the XDR-TB cohort or state 
whether the MDR-TB cohort includes any XDR-TB case. This further hampers XDR-TB 
prevalence data in Africa.  
 
Anti-tuberculosis drug-resistance susceptibility testing surveys provide data to ascertain the 
level of drug-resistance in each country (1). This is important especially in countries where not 
all TB patients receive routine DST for anti-TB drugs(1). The level of out-dated TB drug-
resistance prevalence data in certain African countries is evident when considering that 
countries like Angola, Congo and Liberia have never carried out an anti-tuberculosis drug-
resistant survey.  Furthermore, Botswana, Zambia, and Mozambique last conducted anti-
tuberculosis drug-resistant surveys in the 2005-2009 (1). Therefore, it would be beneficial if 
African countries regularly conduct drug-resistance surveys to ensure current anti-tuberculosis 
drug-resistance data.  
 
In recent years, however, the number of countries which conducted anti-tuberculosis drug-
resistance surveys has slightly increased. During 2015-2016, Burkina Faso, Ghana, and 
Zimbabwe completed anti-tuberculosis  drug-resistance surveys for the first time (1). This 
increases available data regarding drug-resistance in Africa and inform healthcare drug-
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resistant policies in Africa. The increase in number of countries conducting drug-resistance 
testing could be due to increased availability of TB/diagnostic equipment such as the Xpert 
MTB/RIF test.   However, the reported prevalence of XDR-TB in Africa could still be an 
underestimation due to lack of laboratory capacity to conduct DST for second-line anti-
tuberculosis drugs in countries in Africa  (27). In cases where second-line DST was performed 
on MDR-TB cases DST only included testing for kanamycin and ofloxacin (17).  This could 
potentially lead to the underdiagnosis of XDR-TB cases resulting in the underestimation of 
XDR-TB prevalence in Africa. 
 
A study conducted in 8 countries in West Africa found that none of the isolates met the criteria 
for XDR-TB diagnosis. However, pre-extensively drug-resistant tuberculosis (Pre-XDR-TB) 
was detected among 21% of the MDR-TB population (20). Data from a genotyping 
surveillance study in Mozambique showed that XDR-TB was not detected in any of the 
isolates, however 7 out of 16 isolates were resistance to fluoroquinolones, indicating the 
presence of Pre-XDR-TB (27). The presence of Pre-XDR-TB in these studies highlights that 
there is a growing burden of Pre-XDR-TB that has potential to result in an increased burden of 
XDR-TB in Africa. 
 
4. Factors associated with the prevalence of DR-TB 
 
Several factors have been reported to be associated with the likelihood of XDR-TB in Africa. 
These factors include, but might not be to limited to; age, sex, sex, HIV status, history of 
previous TB treatment, hospitalization history, CD4 count, weight, smoking status and  
diabetes (3,28–30). These factors are typically reported as characteristics of patients diagnosed 
with XDR-TB and not as factors associated with the likelihood of a diagnosis with XDR-TB 
34 
 
(29). One study explicitly investigated the predictive factors related to XDR-TB (29). 
According to this study HIV status, history of previous TB treatment (treatment failure), and 
history of hospitalization for more than 14 days are independent factors associated with the 
diagnosis of XDR-TB (29).  
 
4.1. Laboratory capacity  
The lack of laboratory capacity in Africa to conduct DST for anti-tuberculosis second-line 
drugs result in samples sent abroad for DST analysis with subsequent delayed diagnosis of 
XDR-TB (26). Currently the WHO recommended  Xpert MTB/RIF diagnostic test is the most 
used DR-TB diagnostic test worldwide including Africa (1).   However this test can only detect 
resistance against Rifampicin, a first-line anti-tuberculosis drug (1). There is no rapid 
diagnostic test to detect TB resistance against second-line drugs within the same time frame as 
the Xpert MTB/RIF test. There is a need to improve access to accurate and rapid TB second-
line anti-tuberculosis testing and thus diagnosis is important. This is emphasised in the End TB 
strategy as one of the objectives for strengthening laboratories (1). 
 
Non-rapid laboratory tests, to detect resistance to second-line anti-tuberculosis drugs, like the 
BACTEC MGIT 960 SL DST kit and the GenoType MTBDRsl are currently used (31). The 
BACTEC MGIT 960 SL DST kit has a higher sensitivity, specificity and accuracy compared 
to the GenoType MTBDRsl (31) as evident from a  systematic review (32). The GenoType 
MTBDRsl sensitivity in detecting kanamycin resistance is the lowest among second-line 
injectable drugs and one in three cases of XDR-TB could be missed (32). This suggests that 
used of the GenoType MTBDRsl test could potentially lead to underdiagnosis of XDR-TB 
which has a bearing on prevalence. A true and accurate diagnosis of XDR-TB is important as 
it enables us to know the true burden of XDR-TB in Africa.  
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The BACTEC MGIT 960 SL being the most accurate DST implies that it is a suitable test for 
detecting XDR-TB. Unfortunately, the GenoType MTBDRsl is not accessible via routine TB 
management in public health facilities (27). This leads us to the conclusion that the most 
accurate diagnostic tool is not accessible to public health facility users thus potentially 
contributing to the underdiagnosis of XDR-TB in Africa. 
 
4.2. Nosocomial transmission  
It is difficult to prove nosocomial transmission in low resource settings, as genome sequencings 
need to be carried out to confirm nosocomial transmission. Furthermore, it needs to be 
established that patients were not infected before they were admitted to the health facility and 
/ or had no prior contact with a suspected index case.  However, nosocomial transmission has 
been associated an XDR-TB outbreak in Kwa-Zulu Natal (33). Furthermore, nosocomial 
transmission of XDR-TB has been suspected as the route of infection of two cases XDR-TB, 
who shared a hospital room with an XDR-TB infected patient, in Mali (26).  
 
Patients infected with XDR-TB are infectious for a longer period of time even after treatment 
has been initiated (12). This means that XDR-TB patients can spread the disease for longer 
period of time and thus putting their contacts at risk of contracting XDR-TB.  It is crucial that 
people infected with XDR-TB are separated from the public for a lengthy period and if possible, 
until cured. The separation is important as it prevents the spread of XDR-TB from infected 
patients to their healthy contacts. 
 
Various TB infection control measures can be applied to prevent the transmission of XDR-TB 
in health facilities (34,35). These measures can include; adequate ventilation in TB wards, 
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wearing of protective clothing and the involuntary detention and isolation of patients who 
refuse treatment (36). 
 
4.3. Discharge into community 
In certain instances patients who programmatically fail XDR-TB treatment are discharged back 
into the community due to limited bed capacity in designated tuberculosis treatment facilities 
(37). The discharged patients have potential to spread XDR-TB to their contacts in the 
community (37).  The prevalence of XDR-TB is thus likely to increase within the communities 
in which XDR-TB patients reside (37).  
 
The practice of discharging patients, who pragmatically failed treatment, into the society goes 
against the principle of preventing XDR-TB transmission by separating infectious patients 
from the TB healthy population. Recent evidence suggests that primary transmission of XDR-
TB is high among XDR-TB infected patients. The majority, 69% (280 out of 404), of XDR-
TB patients in KwaZulu-Natal, South Africa had no history of receiving MDR-TB treatment 
prior to diagnosis (3). This forewarns of XDR-TB primary transmission in the communities, of 
which some could have been caused by uncured patients who are discharged back into the 
community. Furthermore, household contacts of people infected with TB are at risk of 
developing TB and this risk can be as high as 10 times compared to those who were not contacts 
of TB patients (38).  TB infection control needs to be implemented at household and 
community level to prevent the spread of XDR-TB from infectious patients to the healthy 
contacts.  
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4.4. Treatment failure  
Inadequate treatment of MDR-TB is associated with the development of XDR-TB (3). An 
MDR patient from Mali, who developed additional resistance to fluoroquinolones, is suspected 
to have received inadequate treatment for a 6 months period which unsurprisingly resulted in 
the patient developing XDR-TB (26). Ensuring that there are sufficient drugs, including 
appropriate treatment, to treat XDR-TB cases with is very important because even when 
patients are diagnosed with XDR-TB but there  the correct medication to treat them is not 
available, a timely diagnosis will have no significant impact on controlling XDR-TB (26). 
 
4.5. HIV status 
Patients, from South Africa, involved in the outbreak that brought XDR-TB to the global 
attention had a high rate of HIV/TB co-infection (39). However, this is expected since South 
Africa is burdened with HIV/TB co-infection (1). Twenty-three countries in Africa are 
categorised as TB/HIV HBC of which eight have a triple burden namely TB/HIV, MDR-TB 
and TB (Figure 1). However, Ethiopia although categorised as a triple burden country, has low 
HIV burden of  77.4% HIV seronegative TB/HIV co-infection among the DR-TB study cohort 
(40). Thereby correlation between HIV prevalence and HIV/TB co-infection within a 
population needs to be investigated.  
 
4.6. Previous TB treatment 
A history of previous TB treatment is associated with the likelihood of developing DR-TB 
(29,41). This is further supported by evidence from a study done in South Africa, where 95% 
of the patients infected with XDR-TB had a history of a previous diagnosis with MDR-TB 
(37). An Ethiopian case descriptive study found that 82.6% of drug-resistance cases were 
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previously treated for tuberculosis infection (40). This evidence suggests that a history of 
previous TB treatment is a factor associated with development of DR-TB.  
 
4.7.Age 
Current evidence suggest that XDR-TB infection is common among the age group range of 27 
to 43, with a mean age of 34 (3,29,37). 
 
5. The END TB strategy  
 
The End TB strategy is grounded on three pillars: 1) integrated, patient care and prevention 2) 
bold policies and supportive systems and 3) intensified research and innovation (42). The 
strategy will provide TB management guideline programmes until December 2035 (43). 
Furthermore, the strategy envisions a world free of TB and free of mortality and morbidity 
related to TB (44). However this does not mean a notification of zero TB cases, but rather 
reduction of TB notification to less than 10/100 000 in the population and reducing TB related 
deaths by 95% (42). 
 
The End TB strategy demands from all member countries to provide universal access to 
rifampicin DST for all TB cases; access to DST for injectable drugs and fluoroquinolone 
treatment for all TB cases with rifampicin resistance (1). Solving the TB burden in countries 
that account for the majority of the global TB burden is fundamental in achieving the global 
End TB strategy. This systematic review is a contribution to achieving the End TB Strategy 
goals through conducting research to determine prevalence, and factors associated with 
prevalence, regarding XDR-TB in Africa. 
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6. Conclusion  
The lack of national anti-tuberculosis drug-resistance data contributes to the scarcity of DR-
TB prevalence results in Africa. The ultimate difficulty is to ascertain the true drug-resistance 
prevalence in Africa, subsequently leading to misinformed healthcare policies due of 
unavailable and outdated data. A recent systematic review on the prevalence of drug-resistance 
in Sub-Saharan Africa highlighted the importance of having a review that includes XDR-TB 
prevalence in Africa (41). Systematic reviews and meta-analysis have been done on the 
association between DR-TB and various risk factors (41,45,46).  However, none of these 
reviews provided results on the association between XDR-TB and known risk factors 
associated with DR-TB. This systematic review and meta-analysis anticipate filling the gap in 
research. 
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ABSTRACT  
Background: There is a dearth of information regarding prevalence of extensively drug-
resistant tuberculosis (XDR-TB) in Africa.  Although countries in Africa conduct national 
tuberculosis surveys on a regular basis, this information has not been systematically reviewed 
to ascertain the overall prevalence of XDR-TB in Africa.  
Methods: The study aimed to perform a systematic review and meta-analysis of the prevalence 
and factors associated with prevalence of pulmonary XDR-TB among adults in Africa. Eligible 
studies, published between 2006 and 2018, were sourced from various electronic databases 
including PubMed, Scopus, and Web of Science.  Meta-analysis was performed using STATA 
(version 14.2) statistical software. The protocol of this review was registered with PROSPERO, 
reg No CRD42018117037. 
Result: A total of 6242 records were retrieved. Forty-eight studies were screened for eligibility 
and seven, which varied in terms of country setting and study design, were included. The 
prevalence of XDR-TB is 4% (95%CI 2-7) among participants tested for second-line anti-TB 
drug resistance, and 3% (95%1-6) among participants with drug resistant TB. The prevalence 
of XDR-TB was 7% (95%CI 1-18) among participants with MDR-TB. A few studies reported 
on the factors associated with the prevalence of XDR-TB.  
Discussion: The reported prevalence of XDR-TB among participants tested for second-line 
anti-TB drug resistance is low compared to WHO estimates. The systematic review 
underscores a dearth of studies depicting the reality regarding the prevalence of XDR-TB in 
Africa.  Policymakers and stakeholders interested in drug-resistant TB should apply prudence 
when considering XDR-TB prevalence reported for Africa.   
Keywords: prevalence, tuberculosis, extensively drug-resistant tuberculosis, drug resistance, 
drug susceptibility testing 
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1. INTRODUCTION  
Drug-resistant tuberculosis (DR-TB) continues to be a global public health burden. In 2016, 
the World Health Organization (WHO) estimated a global incidence of 600 000 drug-resistant 
TB cases, and extensively drug-resistant TB (XDR-TB) constituted 9.6% of the reported DR-
TB cases (1). XDR-TB is defined as a disease caused by Mycobacterium tuberculosis with 
resistance to at least isoniazid and rifampicin, any fluoroquinolone, and at least one of three 
injectable anti-tuberculosis drugs (amikacin, capreomycin, or kanamycin) (2). To date, 123 
countries have reported at least one case of XDR-TB compared to 92 in 2012, and 55 in 2008 
respectively (3–5). Africa accounts for 13.6% of the global XDR-TB cases, with South Africa 
reporting the highest number (967 out of 1092) of those XDR-TB cases (1). 
 
Available data on the prevalence of XDR-TB in Africa is limited. Although several studies (6–
14) have been conducted in multiple settings in Africa to determine the prevalence of  DR-TB, 
none of these studies reference XDR-TB. The reason why some of these studies could not 
identify XDR-TB is because DST focused on first-line anti-tuberculosis drugs (isoniazid, 
rifampicin, ethambutol, and pyrazinamide) (6–8,14). A few studies have reported prevalence 
of  XDR-TB as 5.9% in Burkina Faso (15), 4.9% in South Africa (16), while Lesotho and Mali 
respectively only reported XDR-TB cases but not the prevalence of XDR-TB (17,18). The true 
prevalence of XDR-TB in Africa is thus unknown as data on the prevalence of XDR-TB has 
not been systematically reviewed to establish the true burden of XDR-TB in Africa. 
 
Several factors have been reported to be associated with the likelihood of XDR-TB in Africa. 
These factors include, but might not be limited to; age, sex, sex, HIV status, history of previous 
TB treatment, hospitalization history, CD4 count, weight, smoking status and  diabetes (19–
22). These factors are typically reported as characteristics of patients diagnosed with XDR-TB 
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and not as factors associated with the likelihood of a diagnosis with XDR-TB (20). One study, 
that explicitly investigated predictive factors related to XDR-TB,  reported HIV status, history 
of previous TB treatment (treatment failure), and history of hospitalization for more than 14 
days as  independent factors associated with the diagnosis of XDR-TB (20).  
 
To date, there have been no published systematic review and or meta-analysis of the prevalence 
of XDR-TB in Africa. Systematic reviews and meta-analysis on the prevalence of MDR-TB 
rather than XDR-TB are reported (23,24). Prevalence rates are central to healthcare policy 
planning and hence the need to ascertain an exact prevalence rate of XDR-TB in Africa.  
Likewise, a meta-analysis of factors associated with the prevalence of XDR-TB in Africa will 
allow us to ascertain and assess the strength of association between associated factors of XDR-
TB prevalence in an African context. The knowledge gained will not only further existing 
academic and clinical understanding of XDR-TB but will similarly enhance clinical 
management.   
 
1.3. Objectives  
1.3.1. Primary objective  
• To assess the prevalence of XDR-TB amongst participants tested for second-line anti-
tuberculosis drug resistance in Africa. 
1.3.2. Secondary objectives  
• To assess the prevalence of XDR-TB amongst participants with resistance to at least 
one anti-TB drug 
• To assess the prevalence of XDR-TB amongst participants with MDR-TB 
• To assess the prevalence of XDR-TB amongst participants with resistance to at least 
one second-line anti-TB drug 
• To assess the factors associated with the prevalence of XDR-TB in Africa.  
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2. METHODS 
The protocol of this systematic review and meta-analysis has been registered with the 
PROSPERO International Prospective Register of systematic reviews. Registration number 
CRD42018117037. 
2.1. Inclusion criteria  
2.1.1. Types of studies  
 
Observational studies, cross-sectional studies, cross-sectional surveys, population-based 
studies and cohort studies were included in this review. 
 
2.1.2. Types of participants 
 
This review included studies reporting laboratory confirmed pulmonary XDR-TB in adults (15 
years and older), irrespective of gender and socio-economic backgrounds. Studies were eligible 
for inclusion if XDR-TB diagnosis was reported based on ay WHO recommended laboratory 
procedures for first line and second line drug resistance testing(25,26).   Studies reported 
patients suspected to have TB were also included. There was no comparison group. 
 
2.1.3. Study setting  
 
This review included studies conducted in Africa.  The following countries were included ; 
Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central 
African Republic, Chad, Comoros, Congo (Brazzaville), Congo (Democratic Republic), Cote 
d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Ethiopia, Gabon,  Gambia, Ghana, 
Guinea, Guinea- Bissau, Kenya, Lesotho, Libya, Liberia, Madagascar, Malawi, Mali, 
Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Reunion, Rwanda, 
Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, Sudan, 
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South Sudan, Swaziland, Tanzania, Togo, Tunisia, Uganda, Western Sahara, Zambia, and 
Zimbabwe (Appendix 1). 
2.2. Exclusion criteria  
• XDR-TB prevalence is not explicitly reported (results are inextricable including other 
types of DR-TB cases) 
• Studies including children, and the results do not differentiate between adults and 
children  
• Studies using study designs other than those mentioned in inclusion criteria study 
design 
• Studies that did not identify/ diagnose/ report on XDR-TB 
• Studies not conducted in Africa 
• Studies not reporting the age range of included participants 
• Studies including participants with extra pulmonary TB 
• Studies whose full-text was not accessible 
• Studies conducted in multi-country and the results are not stratified per country setting 
of study 
• Studies published outside the review period 
• Studies reporting the prevalence without stating the actual proportion of XDR-TB cases 
diagnose 
2.3. Outcome measurements and definition of terms. 
• XDR-TB - as determined by WHO recommended laboratory diagnostic tests (25,26) 
• DR-TB - refers to Mtb that is resistant to at least one anti-TB drug  
• MDR-TB – refers to Mtb that is resistant to both isoniazid and rifampicin. 
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• Second-line resistance - refers to Mtb that is resistant to at least one second-line anti-
TB drug  
 
2.4. Search strategy  
 
We conducted an extensive search of the literature to identify studies relevant to this systematic 
review. The search has an English language limit and time limit for the period 1 January 2006 
up to 31 July 2018. Moreover, we examined the list of references of included study articles to 
identify additional study articles. 
The following keywords were used during the search of articles; tuberculosis, drug resistant 
tuberculosis, multi drug resistant tuberculosis, extensively drug resistant tuberculosis, XDR 
tuberculosis, MDR tuberculosis, XDR TB, MDR TB, mycobacterium tuberculosis, prevalence, 
proportion, rate, statistic, epidemiology, epidemiological, frequency, Africa, risk, associated, 
association, associations, predict, predictor, prediction, predictors, probability, correlation, 
determinant.   
Our search strategy was developed in PubMed using both medical subject headings (MESH) 
and free text (Appendix 2). The search strategy was subsequently then adapted to search for 
studies in other electronic databases. 
 
2.5. Data sources  
 
The electronic databases were searched from 18 September 2018 until 26 September 2018 
and included; PubMed/ Medline, Scopus, Web of Science (excluding PubMed/ Medline and 
zoological records), PyscINFO, Africa-wide Allied Health, Cochrane Central Register of 
Controlled Trials (CENTRAL), CINAHL, Health Source: Nursing Academic, grey literature 
and google scholar. Africa-Wide Allied Health, CINHAL, and Health Source: Nursing 
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Academic databases were accessed through EBSCOhost electronic database. Grey literature 
was sourced from the Open UCT electronic database, WHO global tuberculosis reports from 
2007 to 2018, Google Scholar and screening of reference lists. 
 
A total of 7409 records were retrieved from different electronic databases. The 6242 eligibility 
records that remained, after duplicate records were removed, were accounted for by various 
databases; Africa- Wide Allied Health 2200, CINHAL 111, Cochrane Central 636, Health 
source; Nursing Academic 138, PubMed/ Medline 2307, PsycINFO 27, Scopus 414, Web of 
Science 409 (Table 1). 
 
Table 1: Records retrieved from various electronic databases  
Electronic databases searched  Number of records 
retrieved  
Number of records remaining after duplicates 
records were removed 
Africa- Wide Allied Health 2473 2200 
CINHAL 207 111 
Cochrane Central 714 636 
Health source; Nursing Academic 219 138 
PubMed/ Medline 3266 2307 
PsycINFO 42 27 
Scopus 448 414 
Web of science 440 409 
Total 7409 6242 
 
2.6. Study selection  
 
One author screened all the titles and abstracts of the identified study records. Two authors 
then read the headings and abstracts of the initially included articles with the purpose of 
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selecting potential eligible studies. Full text articles were independently reviewed by two 
authors (PK and EP). A third author (JN) was consulted regarding any disagreement or 
uncertainties regarding the inclusion or exclusion of articles into this review. 
Data extraction and management 
Two authors (PK and EP) independently extracted data from full text of eligible articles was 
using a standardized data extraction form (Appendix 3). The data extraction was piloted and 
modified to enhance the robustness of the data being extracted. 
The following study characteristic were extracted; country of study, study design, condition of 
interest, study duration, diagnostic criteria, study population, age range of participants, data 
sources, sample size, and outcome measures. Each study contributed one outcome measure of 
interests. In case on missing data, corresponding or first authors of published articles were 
contacted to provide further details. 
A third author (JN) was consulted whenever there was an uncertainty regarding the data 
extracted.  
Assessment of risk of bias in included studies 
The quality of included studies was assessed using the quality assessment tool developed by 
Hoy et al. 2012, and modified by Werfali et al. 2014 (27,28).  The prevalence study quality 
appraisal tool categorises studies into three groups; 0-5 points as high-risk studies, 6-8 points 
as moderate risk studies, and >8 as low risk studies (Table 2). The Newcastle-Ottawa appraisal 
tool was be used to appraise cohort studies included in this review (29,30). The Newcastle-
Ottawa appraisal tool was modified to suit use for this review.  
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The first author assessed the quality of all included studies. The second author validated the 
quality appraisal script of the included studies script. Disagreement on the quality scores was 
resolved by unanimity between the two authors. 
Table 2. Assessment criteria for prevalence studies  
Items Quality score  
External validity  
 
1. Was the study’s target population a close representation of the national 
population in relation to relevant variables? 
(1 point) 
2. Was the sampling frame a true or close representation of the target 
population? 
(1 point) 
3. Was some form of random selection used to select the sample, OR was a 
census undertaken? 
(1 point) 
4. Was the likelihood of non-response bias minimal? (1 point) 
 Total (4 points) 
Internal validity  
 
1. Were data collected directly from the participants (as opposed to a proxy)? (1 point) 
2. Was an acceptable case definition used in the study? (1 point) 
3. Was the study instrument that measured the parameter of interest shown to 
have validity and reliability? 
(1 point) 
4. Was the same mode of data collection used for all participants? (1 point) 
5. Was the length of the shortest prevalence period for the parameter of interest 
appropriate? 
(1 point) 
6. Were the numerator(s) and denominator(s) for the parameter of interest 
appropriate? 
(1 point) 
 Total (6 points)  
Summary item on the overall risk of study bias 
Overall score Quality 
>8 points Low Risk: Further research is unlikely to change our confidence in the estimate 
6-8 points Moderate Risk: further research is likely to have an important impact on our confidence in the estimate 
and may change the estimate  
0-5 points High Risk: Further research is very likely to have an important impact on or confidence in the estimate 
and is likely to change the estimate 
*Quality assessment tool as developed Hoy et al. (27) and modified by Werfali et al. 2014 (28). 
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2.7. Statistical methods, heterogeneity and analysis  
The statistical software Stata version 14.2 was used to carry out the meta-analysis. The user-
written metaprop command was used to calculate the prevalence of XDR-TB among 
participants groups of interest (31). An application of random effect (random) command was 
used to take into account the heterogeneity of the included studies. We used the Freeman-Tukey 
Double Arcsine Transformation (ftt) method to stabilize the variances (31). The 95% 
confidence interval was used to provide a range of the estimated prevalence. 
  
Statistical heterogeneity of the included studies was assessed using the Chi-squared test of 
homogeneity. Chi-squared results were considered statistically significant at alpha level 
0.10 (32). Statistical heterogeneity was further assessed using the I2statistic. The I2 squared 
statistic results are reported as a percentage value (32). During the meta-analysis process, 
studies were subgrouped according to their study setting. Studies were further grouped 
according to their MDR-TB HBC status when we assessed the prevalence of XDR-TB among 
countries categorised as MDR-TB HBC. Study authors were contacted via the provided email 
of the corresponding author to request for additional information and clarity on the reported 
study information. 
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3. RESULTS  
3.1. Literature search  
 
The screening of study records is reported using the Preferred reporting Items for Systematic 
Reviews and Meta-analysis (PRISMA) format (33) (Appendix 4). 
A total of 7409 records were retrieved from all the identified databases. EndNote version X9 
referencing software was used to remove 1167 duplicates.  Tittle and abstracts of 6242 articles 
were screened for potential eligibility resulting in excluding 6194.  Forty-eight (48) full-text 
articles were screened for eligibility and 7 studies met the inclusion criteria (Figure 1). 
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Figure 1: PRISMA flow diagram process followed to include articles eligible to review 
regarding XDR-TB prevalence in Africa 
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3.2. Characteristics of studies 
This review includes 7 studies, published from 2008 to 2018 (Table 3). Three studies were 
conducted in South Africa (34–36), one in multiple countries including South Africa (37), and 
one each in Swaziland, Uganda, and Morocco  (38–40). All studies included participants older 
than 14 years. Only two studies (38,39) were conducted on a national level. The characteristics 
of the excluded studies are summarised in Table 4. 
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Table 3: The characteristics of studies included in the systematic review of XDR-TB prevalence in Africa 
Study ID Study 
duration 
Country of 
study 
Study design  Study population  
 
No of 
participants 
with TB  
No of 
XDR-
TB 
DST method Drugs tested for 
resistance  
Bantubani 
2014 (34) 
Phase 1: 
August 2007-
August 2009 
 
Phase 2: 
August 2008 
– November 
2009 
South Africa Cross-sectional study  
Subnational study  
Conducted in Hospitals 
in Kwa-Zulu Natal 
Adult inpatients reporting 
“coughing” 
>18 years 
 Age median 37 (30-48) 
543 16 Middlebrook 7H11 selective 
agar (Difco) and liquid 
medium (BACTEC MGIT 
960, Becton Dickenson 
Diagnostics) 
INH, RMP, SM, 
EMB,ETH, OFX, 
KAN, CPM 
Cox 2010 
(35) 
May 2008 – 
November 
2008 
South Africa Cross-sectional survey 
Subnational survey  
Conducted in two 
primary care clinics in 
Khayelitsha, Cape 
Town 
Clinic attendees suspected 
for pulmonary tuberculosis 
Not currently on treatment   
> 18 years  
 
535 2 BACTEC MGIT 960 system, 
Hain GenoType 
MTBDRplus,   
Ziehl-Neelsen staining and 
p- nitrobenzoic acid testing 
INH, RMP, SM, 
EMB, PZA, ETH, 
OFX, KAN, CPM, 
AMK 
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Dalton 
2012 (36) 
January 2005 
– December 
2008 
Multi-country 
including 
South Africa 
Population based study 
Subnational study 
Conducted in four 
provinces of South 
Africa (Eastern Cape, 
KwaZulu Natal, 
Mpumalanga, and 
Northwest 
Adults within the 
catchment areas with 
locally confirmed, 
pulmonary MDR-TB who 
started treatment with 
second-line drugs 
>18 years 
293 31 Middlebrook 7H10 agar 
(BD) 
 
INH, RMP, SM, 
EMB, ETH, OFX, 
KAN, CPM, AMK, 
CPX, amino salicylic 
acid 
Ennassiri, 
2017 (38) 
2015 Morocco Cohort study 
National 
 
MDR-TB patients amongst 
suspected DR-TB patients 
whose strain were sent to 
NTRL in the National 
Institute of Hygiene (NIH) 
(Rabat, Morocco) 
Age range 15-72 years 
155 4 Lowenstein– Jensen (LJ) 
medium 
INH, RMP, EMB, 
SM, OFX, KAN, 
AMK 
 
 
Jacobson 
2017 (37) 
November 
2012 -
December 
2013 
South Africa 
 
Prospective 
observational study 
Conducted in 3 
provinces 
Adults diagnosed with RIF-
resistant MTB by Expert 
≥18 years) 
497 6 MTB/RIF (Xpert; Cepheid, 
California), MTBDRplus 
LPA (version 2),  BACTEC 
MGIT 960 system culture 
(BD Diagnostics Systems, 
Maryland) 
INH, RMP, PZA, 
ETH, OFX, KAN, 
AMK  
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(Eastern Cape, 
Gauteng, and Free 
State) 
Sanchez-
Padilla 
2012 (39) 
May 2009 - 
February 
2010 
Swaziland 
(Now known 
as Eswatini) 
Cross-sectional survey 
National survey 
Consecutive smear-
positive patients who were 
given a new diagnosis of 
TB 
>14 years of age 
Age median 33 (27-41) 
658 1 BACTEC MGIT 960 system 
(Becton Dickinson) , 
Löwenstein-Jensen and 
Stonebrink, GenoType 
MTBC test (HAIN 
Lifescience GmbH, Nehren, 
Germany) 
INH, RMP, SM, 
EMB, PZA, ETH, 
OFX, CPM, AMK, 
MOX, 4-
aminosalicylic acid 
Temple 
2008 (40) 
July 2003 – 
November 
2006 
Uganda Cohort study 
Subnational study 
NTLP clinic Mulonga 
Hospital in Kampala 
   
Consecutive treatment-
experienced patients with 
TB 
>18 years 
410 1 BACTEC 460, BACTEC 
MGIT 960, Middle Brook 
7H10 agar 
INH, RMP, SM, 
EMB, PZA, ETH, 
OFX, KAN, CPM, 
para-amino salicylic 
acid 
Abbreviations; TB= tuberculosis, NIH= National Institute of Hygiene, NTLP=National Tuberculosis and Leprosy Programme, DST= drug susceptibility testing, DS-TB=drug 
susceptible tuberculosis, DR-TB= drug-resistant tuberculosis, INH=Isoniazid, RMP=rifampicin, SM=streptomycin, EMB= ethambutol, PZA= pyrazinamide, ETH= ethionamide, 
OFX= Ofloxacin, KAN= kanamycin, CPM = Capreomycin, AMK= Amikacin, MOX= moxifloxacin, CPX= ciprofloxacin  
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Table 4: Characteristics of excluded studies 
Author Study tittle Reason for exclusion  
XDR-TB diagnosis 
Meriki 2013 Drug Resistance Profiles of Mycobacterium tuberculosis Complex and Factors Associated with Drug 
Resistance in the Northwest and Southwest Regions of Cameroon 
 
 
 
 
 
 
 
 
 
 
 
No case of XDR-TB was detected  
Diarra 2016 Tuberculosis drug resistance in Bamako, Mali, from 2006 to 2014 
Hoza 2015 Anti-TB drug resistance in Tanga, Tanzania: A cross sectional facility-base prevalence among pulmonary TB 
patients 
Lukoye 2013 Anti-Tuberculosis Drug Resistance among New and Previously Treated Sputum Smear-Positive Tuberculosis 
Patients in Uganda: Results of the First National Survey 
Lukoye 2011 Rates of Anti-Tuberculosis Drug Resistance in Kampala- Uganda Are Low and Not Associated with HIV 
Infection 
Kapata 2017 Outcomes of multidrug-resistant tuberculosis in Zambia: a cohort analysis 
Kaswa 2014 Pseudo-Outbreak of Pre-Extensively Drug-Resistant (Pre-XDR) Tuberculosis in Kinshasa: Collateral Damage 
Caused by False Detection of Fluoroquinolone Resistance by GenoType MTBDRsl 
Umubyeyi 2008 Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates 
from Rwanda 
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Ibrahim 2017 Pattern of prevalence, risk factors and treatment outcomes among Egyptian patients with multidrug resistant 
tuberculosis 
 
 
 
 
 
Veldsman 2009 The prevalence of isoniazid and rifampicin resistance of Mycobacterium tuberculosis 
 
 
Study includes children 
Bhembe 2014 Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from 
DNA isolated from tuberculosis patients in the Eastern Cape province South Africa 
Results included age group <20 years. 
Agonafir 2010 Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia Included participants aged 10-75 years. 
Results did not differentiate children.  
Osei-Wusu 2018 Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant 
tuberculosis case 
Minimum age of participants was 13 
years. 
Schnippel 2015 Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the 
South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register 
Results included <15year age group. 
Avalos 2015 Prevalence and Risk Factors of Drug Resistant Mycobacterium Tuberculosis in a Multisite Cohort Study Included patients of at least 5 years of 
age. 
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Said 2012 Molecular characterization and second-line anti-TB drug-resistance patterns of multidrug resistant 
tuberculosis isolates from the northern region of South Africa 
Included participants aged 6 to 69 
years. Results do not differentiate 
children  
Calver 2010 Emergence of Increased Resistance Tuberculosis Despite Treatment and Extensively Drug-Resistant 
Adherence, South Africa 
Assumed included children (“All mine 
employees and dependents with drug-
resistant TB” were included in the 
study) 
Loveday 2017 Drug-resistant tuberculosis in patients with minimal symptoms: favorable outcomes in the absence of 
treatment 
Included participants aged 14 years. 
Gadallah 2015 Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt Included participants aged 7 to 76 
years. Results do not differentiate 
children 
Seung 2009 Early Outcomes of MDR-TB Treatment in a High HIV- Prevalence Setting in Southern Africa Included participants aged 3-62.Results 
do not differentiate children 
Schnippel 2016 Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in 
South Africa: a retrospective cohort study 
Included participants <15 years  
Study design 
Andrews 2010 Predictors of Multidrug- and Extensively Drug-Resistant Tuberculosis in a High HIV Prevalence Community Case-control study 
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Gandhi 2010 HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality XDR-TB diagnosis already known at 
enrolment into the study 
O’Donell 2011 Extensively drug-resistant Tuberculosis in Women,KwaZulu-Natal, South Africa Case-control study 
Millan-Lou 2016 Mycobacterial diversity causing multi- and extensively drug- resistant tuberculosis in Djibouti, Horn of Africa Genotypic lineage study 
Van der Plas 
2011 
High prevalence of comorbidity and need for up-referral among inpatients at a district-level hospital with 
specialist tuberculosis services in South Africa – the need for specialist support 
Cross-sectional hospital based study 
interrogating typical patient types, including co-
morbidities. No diagnostic tests carried 
out. 
Age range of participants not stated  
Gandhi 2006 Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV 
in a rural area of South Africa 
 
 
 
Age range not stated. 
Age range cannot be implied from 
results. 
Olle-Goig 2011 Resistance to anti-tuberculosis medications in the Horn of Africa 
Moodley 2011 Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa 
Saleri 2010 Extensively Drug-Resistant Tuberculosis in Burkina Faso 
Mlambo 2008 Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa 
Results include extra-pulmonary TB cases 
Shin 2017 High Treatment Success Rates Among HIV-Infected Multidrug-Resistant Tuberculosis Patients After 
Expansion of Antiretroviral Therapy in Botswana, 2006–2013 
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Evans 2017 Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa  
Results include extra-pulmonary TB Loveday 2012 Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, 
South Africa 
Chingonzoh 
2018 
Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting 
database in the Eastern Cape Province, South Africa, 2011 to 2013 
Specimen type not stated. Results 
could include extra-pulmonary TB  
Full text not available 
Allanana 2012 Prevalence of mycobacterium tuberculosis infection among Jos prison inmates and comparison three 
diagnostic methods 
 
 
Full text not available 
Sanogo 2017 Acquisition of proper treatment for Extensively Drug Resistant tuberculosis patients in Mali: Where is the 
issue? 
Multi-country studies with un-stratified results 
Bastard 2018 Outcomes of HIV-infected versus HIV-non- infected patients treated for drug-resistance tuberculosis: 
Multicenter cohort study 
Multiple country study. Results not 
stratified per country included in study.  
 Cegielski 2014 Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis 
Non-African study setting  
Batbold 2017 Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an 
adjunct immunotherapy in 269 patients with pulmonary tuberculosis 
 
 
Study conducted in Ukraine and 
Mongolia 
68 
 
Study reports estimates 
Ismail 2018 Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national 
cross-sectional survey 
Estimates reported versus actual 
number of XDR-TB cases detected. 
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3.3. Assessment of risk of bias in included studies 
The quality of cross-sectional studies, cross-sectional surveys and population based studies 
were assessed using an quality assessment tool by Hoy et al. 2012 (27) as adapted by Wefarli 
et al. 2014 (28) (Table 5). Most of the articles were of moderate risk; one study was considered 
as low risk (34) and none were of high risk. Three studies (35,36,39) did not state the sampling 
method used and three (34,37,38) had a high risk of non-response bias, since the response rate 
was less than 75% in these studies. All studies collected data from the patients directly. The 
case definition of XDR-TB was determined before the commencement of the studies. 
 
Table 5: Assessing risk of bias in included studies  
Study ID External validity Internal validity Quality 
score 
Risk of bias 
A1 A2 A3 A4 B1 B2 B3 B4 B5 B6 
Bantubani 2014 
(68) 
1 1 1 0 1 1 1 1 1 1 9 Low 
Cox 2010 (35) 1 0 UN 1 1 1 1 1 1 1 8 Moderate 
Dalton 2012 
(36) 
0 1 UN 1 1 1 1 1 1 1 8 Moderate 
Ennassiri, 2017 
(38) 
1 1 1 0 1 1 1 UN UN 1 7 Moderate 
Jacobson 2017 
(37) 
1 1 UN 0 1 1 1 1 1 1 8 Moderate 
Sanchez-Padilla 
2012 (39) 
1 1 UN 1 1 1 1 1 UN 1 8 Moderate 
EXTERNAL VALIDITY: A1, Representative of the target population; A2, Appropriate recruitment of the 
participants, A3 Appropriate sampling frame, A4 Minimal non-response bias INTERNAL VALIDITY:B1 Data 
collected directly from the subjects (as opposed to a proxy), B2 Acceptable case definition, B3 valid and reliable 
study instrument, B4 same mode of data collection used for all subjects, B5 Appropriate shortest prevalence 
period for the parameter of interest, B6 Appropriate numerator(s) and denominator(s) for the parameter of 
interest.   
SCORE: 1 indicates the study met the criteria; 0 indicates the study did not meet the criteria, UN indicates the 
response was unclear.  
INTERPRETATION Quality score: 0-5 high risk of bias; 6-8 moderate risk of bias; >8 Low risk of bias 
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Cohort studies were assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS) 
for case-control studies (41) (Table 6).   The only study with a cohort study design (40) had a 
high-risk quality score as there was no control or comparison group.  XDR-TB cases were 
already diagnosed at enrolment, not during the study.  
 
Table 6: Assessment of risk of bias for cohort studies 
Study ID Selection Comparability Outcome Quality score 
(per study) 
Risk of 
bias 
A1 A2 A3 A4 B1 C1 C2 C3 
Temple 2008 
(40) 
0 0 1 UN 0 1 1 0 3 High 
A. SELEECTION OF THE STUDY GROUPS (A1 Representativeness of the exposed cohort, A2 selection of 
the non-exposed cohort, A3 ascertainment of exposure, A4 Demonstration that outcome of interest was not 
present at the start of the study);  B. Comparability (B1 comparability of the cohorts on the basis of the design 
and analysis) C. Outcome ascertainment of the exposure (C1 Assessment of outcome C2 Was follow-up long 
enough for outcome to occur C3 Adequacy of follow up of cohorts) 
Quality score: 0-5 High risk of bias, 6-8 Low risk of bias 
 
3.4. Synthesis of results 
3.4.1. Prevalence of XDR-TB in Africa 
 
All seven studies reported on the proportion of XDR-TB cases among the study population. 
Studies differed regarding study design, study population and reporting format necessitating 
subgroup analysis of the studies included in the quantitative analysis of XDR-TB prevalence 
in Africa.  
The size of cohorts, diagnosed with pulmonary TB, in the 7 studies ranged from 155 – 658 
adults (Table 7). The proportion of individuals diagnosed with DS-TB  (34,35,39) is not 
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reflected in Table 7 as the objective of the systematic review was to determine the prevalence 
of XDR-TB.   
Six (6) studies reported the number of participants, as ranging from 104 to 497 per study, 
with resistance to any first- and / or second-line anti-tuberculosis drug. Six (6) studies 
reported the number of participants with MDR-TB, which ranged from 18 to 155 per study 
(Table 7). 
All 7 studies conducted second-line anti-tuberculosis DST on a total of 1243 participants, a 
range of 51 to 472 patients per study.   However, only four (4)  studies (35,37–39) reported 
results indicating resistance to any second-line anti-TB drug.  A range of 8 – 98 individuals, 
per study, were resistant to any second-line anti-tuberculosis drugs (Table 7).   
All studies reported on the number of XDR-TB participants, ranging from 1 – 31 per study 
(Table 7).   A total of 61 XDR-TB patients were identified among 1243 participants who 
were tested for second-line anti-tuberculosis drug resistance. 
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Table 7: Comparison of XDR-TB prevalence among various TB cohorts based on second-line anti-TB drug resistance testing. 
Study ID Study 
year 
Country Study design 
description 
Study population 
description 
 
Particip
ants 
with TB 
Participants with 
drug resistant TB 
resistant to any  
(first and/or second-
line) anti-TB drug 
No of 
participants 
with  
MDR-TB 
Participants 
tested for 
resistance to 
second-line 
anti-TB drugs 
Participants 
resistant to 
second-line 
anti-TB 
drugs 
No of 
participants 
with  
XDR-TB 
Bantuban
i 2014 
(34) 
2007-
2009 
South 
Africa 
Cross-sectional study  
Subnational study  
Conducted in 
Hospitals in Kwa-Zulu 
Natal 
Adult inpatients reporting 
“coughing” 
>18 years 
 Age median 37 (30-48) 
543 104 84 472 Not stated 16 
Cox 2010 
(35) 
2008 South 
Africa 
Cross-sectional survey 
Subnational survey  
Conducted in two 
large primary care 
clinics in Khayelitsha, 
Cape Town 
Clinic attendees suspected 
of pulmonary tuberculosis 
Not currently on treatment   
> 18 years  
535 105 18 22 8 2 
Dalton 
2012 (36) 
2005 
- 
2008 
Multi-
country 
including 
South 
Africa 
Population based 
study Subnational 
study 
Conducted in four 
provinces of South 
Africa (Eastern Cape, 
KwaZulu Natal, 
Adults within the 
catchment areas including 
locally confirmed, 
pulmonary MDR-TB who 
started treatment with 
second-line drugs 
>18 years 
293 Not stated 142 293 Not stated 31 
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Mpumalanga, and 
Northwest) 
Ennassiri, 
2017 (38) 
2015 Morocco Cohort study 
National 
 
MDR-TB patients amongst 
suspected DR-TB patients 
whose strain were sent to 
National Tuberculosis 
Reference Laboratory 
(NTRL) in the National 
Institute of Hygiene (NIH) 
(Rabat, Morocco) 
Age range 15-72 years 
155 155 155 153 22 4 
Jacobson 
2017 (37) 
2012 
-2013 
South 
Africa 
Prospective 
observational study 
Conducted in 3 
provinces 
(Eastern Cape, 
Gauteng, and Free 
State) 
Adults diagnosed with RIF-
resistant MTB by Xpert 
≥18 years) 
497 497 Not stated 130 98 6 
Sanchez-
Padilla 
2012 (39) 
2009 
- 
2010 
Eswatini 
(formerly 
Swaziland) 
Cross-sectional survey 
National survey 
Consecutive smear-
positive patients who were 
given a new diagnosis of 
TB 
>14 years of age 
Age median 33 (27-41) 
658 
 
 
 
 
193 122 122 72 1 
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Temple 
2008 (40) 
2003 
– 
2006 
Uganda Cohort study 
Subnational  
NTLP clinic Mulonga 
Hospital in Kampala 
   
Consecutive treatment-
experienced patients with 
TB 
>18 years 
410 
 
115 52 51 Not stated 1 
Note:  
No of participants with TB= refers to participants diagnosed with pulmonary mycobacterium tuberculosis  
No of participants with resistant to any (first- and/or second-line) anti-TB drug= refers to participants who are resistant to at least one anti-TB drug 
No of participants with MDR-TB= refers to participants who are diagnosed with MDR-TB  
No of participants with second-line resistance= refers to participants who are resistant to at least one second-line anti-TB drug  
No of participants with XDR-TB= refers to participants diagnosed with XDR-TB 
Abbreviations; TB= tuberculosis, DST= drug susceptibility testing, DR-TB=drug-resistant tuberculosis, MDR-TB= multi drug-resistant tuberculosis, XDR-TB= extensively drug-resistant 
tuberculosis 
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3.4.2. Prevalence of XDR-TB amongst participants tested for second-line anti-TB drug 
resistance 
The pooled prevalence of XDR-TB in those tested for second-line anti-TB drug resistance is 
4% [95% Confidence Interval (CI), 2% to 7%; n=1243 adults;  I2  = 77.15%] (Figure 2). By 
country, South Africa had the highest prevalence at 6% (95% CI, 2% to 11%; n=972;  I2  = 
81.6%).  
 
ES= estimated prevalence, CI=confidence interval, MDR-TB =multi drug-resistant tuberculosis, XDR-TB = 
extensively drug-resistant tuberculosis 
Figure 2:  Subgroup analysis of the prevalence of XDR-TB amongst participants tested 
for second-line anti-TB drug resistance.  
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3.4.3. Prevalence of XDR-TB amongst participants with DR-TB  
The pooled prevalence of XDR-TB in those with DR-TB is 3% (95% CI, 1% to 6%; n=1169; 
I2=85.39% (Figure 3). By country, South Africa had the highest prevalence at 5% (95% CI, 
0% to 14%; n=706)  
 
 
ES= estimated prevalence, CI=confidence interval, DR-TB =drug-resistant tuberculosis, XDR-TB = extensively 
drug-resistant tuberculosis. 
Figure 3: Subgroup analysis of the prevalence of XDR-TB amongst participants with 
resistance to at least one anti-TB drug 
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3.4.4. Prevalence of XDR-TB amongst participants with MDR-TB  
The pooled prevalence of XDR-TB in those with MDR-TB is 7% (95% CI, 1% to 18%; 
n=573; I2=91.71% (Figure 4). By country, South Africa had the highest prevalence at 20% 
(95% CI, 15% to 25%; n=244).    
 
ES= estimated prevalence, CI=confidence interval, MDR-TB =multi drug-resistant tuberculosis, XDR-TB = 
extensively drug-resistant tuberculosis. 
Figure 4:  Subgroup analysis of the prevalence of XDR-TB amongst participants with 
MDR-TB  
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3.4.5. Prevalence of XDR-TB amongst participants with resistance to at least one second-line 
anti-tuberculosis drug 
The pooled prevalence of XDR-TB in countries with resistance to at least one second-line 
anti-TB drug is 7% (95% CI, 1% to 18%; n=200; I2=71.24% (Figure 5). By country, Morocco 
had the highest prevalence at 18% (95% CI, 5% to 40%; n=22).   
 
ES= estimated prevalence, CI=confidence interval, second-line= second-line anti-tuberculosis drug 
resistance, XDR-TB = extensively drug-resistant tuberculosis. 
Figure 5: Subgroup analysis of the prevalence of XDR-TB amongst participants with 
resistance to at least one second-line anti-tuberculosis drug. 
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3.4.6. Subgroup analysis of the prevalence of XDR-TB in Africa according to WHO TB high 
burden country categories  
 
The pooled prevalence of XDR-TB in those countries with a high burden of MDR-TB is 6% 
(95% CI, 2% to 11%; n=917; I2=81.6% (Figure 6). The pooled prevalence of XDR-TB in those 
countries with a low burden of MDR-TB is 2% (95% CI, 0% to 4%; n=326; I2=81.6%).   
 
ES= estimated prevalence, CI=confidence interval, DST= drug susceptibility testing, MDR-TB= multi drug 
resistant tuberculosis XDR-TB = extensively drug-resistant tuberculosis, HBC= high burden country. 
 Figure 6: Subgroup analysis of the prevalence of XDR-TB in Africa as per MDR-TB 
HBC. 
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3.4.7. Subgroup analysis of the prevalence of XDR-TB in Africa by studies quality score 
categories. 
 
The pooled prevalence of XDR-TB in studies with a low risk of bias is 3% (95% CI, 2% to 
5%; n=472), moderate risk of bias is 4% (95% CI, 1% to 9%; n=720; I2=82.2%), and in 
studies with a high risk of bias is  2% (95% CI, 0% to 10%; n=51)  (Figure 7). 
 
ES= estimated prevalence, CI=confidence interval, DST =drug susceptibility testing, XDR-
TB = extensively drug-resistant tuberculosis 
Figure 7:  Subgroup analysis of the prevalence of XDR-TB in Africa by studies quality 
score categories.  
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3.4.8. Subgroup analysis of the prevalence of XDR-TB in Africa by sample size categories. 
 
The pooled prevalence of XDR-TB in those studies with a sample size greater than 100 is 4% 
(95% CI, 2% to 8%; n=1170; I2=83.7%) (Figure 8). The pooled prevalence of XDR-TB in 
those studies with a sample size less than 100 is 3% (95% CI, 2% to 7%; n=73).  
 
ES= estimated prevalence, CI=confidence interval, DST =drug susceptibility testing, XDR-
TB = extensively drug-resistant tuberculosis, Sample Size= The number of people tested 
for second-line anti-TB drug resistance per study 
Figure 8:  Subgroup analysis of the prevalence of XDR-TB in Africa by sample size 
categories.  
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3.4.9. Factors associated with the prevalence of XDR-TB in Africa 
 
Among studies reporting on the prevalence of XDR-TB two (34,38) reported on factors, HIV 
status and previous TB treatment, associated with the prevalence of XDR-TB in Africa (Table 
8). All participants were HIV infected in the one study that reported HIV status of XDR-TB 
participants (38). History of previous TB treatment was reported in 9/16 (56.5%) and 4/4 
(100%) participants respectively (34,38).  
Table 8: Summary of factors reported associated with the prevalence of XDR-TB in 
Africa 
Factor associated with XDR-TB prevalence Study reporting on this factor Summary value (%) 
HIV status (38) 4/4 (100%) 
History of previous TB treatment  (34,38) 9/16 (56.5%)  
4/4 (100%) 
 
3.5. Heterogeneity in included studies  
There is considerable heterogeneity (I2=77.15%) among included studies as expected with 
prevalence studies given clinical heterogeneity, different study procedures and study 
populations. Additionally, the high heterogeneity among the included studies could have been 
influenced by chance, different outcome measure and diagnostic tests.  To account for this, 
we applied the Freeman-Tukey Double Arcsine Transformation (ftt) method to estimate the 
random effects pooled prevalence of XDR-TB in the various groups and subgroups studied.   
We were unable to generate a funnel plot to examine for publication bias, given the small 
number of studies. 
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3.6. Grading the quality of evidence 
We were unable to apply GRADE because of limited information about factors associated with 
the prevalence of XDR-TB reported. 
4. DISCUSION  
This systematic review found a prevalence of XDR-TB in Africa of 4% amongst participants 
tested for second line anti-TB drug resistance, 3% among participants with DR-TB, and 7% 
among participants with MDR-TB. This suggests that the burden of XDR-TB is high among 
the people infected with MDR-TB compared to adults infected with DR-TB. HIV infection and 
the history of previous TB treatment are factors associated with the prevalence of XDR-TB in 
Africa. 
The pooled prevalence of XDR-TB among those with drug resistance is close to the reported 
burden of 3.9% of XDR-TB among MDR/RR-TB cases (1). The WHO reported global 
prevalence (6.2%) of XDR-TB among MDR-TB (1) is close to the one found by this review 
among participants with MDR-TB. The similarity of XDR-TB prevalence in those with MDR-
TB and those with resistance to second-line anti-TB drugs could be due to the fact that second-
line anti-TB drugs are used in the treatment of MDR-TB (42). The pooled prevalence of XDR-
TB in South Africa among participants with MDR-TB is high compared to the reported 
prevalence of XDR-TB at 4.9% among confirmed MDR-TB cases in SA (43). The factors 
associated with XDR-TB prevalence identified by this review have also been associated with 
XDR-TB in other studies conducted in Africa (20,44). 
 
Among the countries included in this systematic review, South Africa is the only country that 
is categorized as an MDR-TB high burden country while both Uganda and Swaziland are listed 
as a TB/HIV high burden country. Morocco, although having a high prevalence of XDR-TB 
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amongst participants with resistance to any second-line anti-TB drug (Figure 5), is not part of 
any TB related HBC category (1). Moreover, South Africa is the only triple high burden 
country included in this systematic review. The pooled prevalence of subgroup analysis by 
MDR-TB burden categories show a that MDR-TB high burden countries is 4% higher than in 
countries not categorized as MDR-TB high burden. Subgroup analysis show that the prevalence 
of XDR-TB is two times higher at 20%) in South Africa than the overall prevalence of XDR-
TB at amongst participants with MDR-TB. This suggest that South Africa has a high burden 
of XDR-TB among participants with MDR-TB compared to other countries in Africa. 
 
The prevalence of XDR-TB in Africa in the quality score subgroup category of studies with a 
moderate risk of bias is 4% which is the same as the overall pooled estimate prevalence of 
XDR-TB in Africa. The quality score subgroup category of studies with a high risk of bias is 
2% which is low than the overall pooled prevalence estimates of XDR-TB in Africa. This 
consequently reduces the likelihood of an overestimation influence on the overall pooled 
prevalence of XDR-TB in Africa by studies with a high risk of bias. The estimated pooled 
prevalence of XDR-TB in Africa is 1% higher in studies with sample sizes greater than 100 
compared to studies with less than 100 participants.  In exploring the sensitivity of the overall 
pooled estimate of the prevalence of XDR-TB in Africa we conducted multiple subgroup 
analysis and compared the subgroup estimates with the overall pooled estimate and observed 
that the overall pooled estimate prevalence was sensitive during subgroup analysis by country 
and by WHO HBC. 
 
 
85 
 
We found a dearth of studies measuring the prevalence of pulmonary XDR-TB whereas the 
few studies that did measure the prevalence of XDR-TB reported a combined prevalence 
inclusive of both pulmonary and extra-pulmonary TB. Moreover, some papers lacked 
information about the age range of participants and specimens collected. The lack of this 
information in papers made it difficult for us to know the age range and type of TB infecting 
the study participants.  Consequently, the papers lacking the information required for study 
inclusion into this review were excluded. Furthermore, attempts to get additional information 
from study authors were unsuccessful. As only two studies reported factors associated with 
XDR-TB prevalence, a meta-regression was not done. The limited data about factors associated 
with XDR-TB in this review could be explained by the fact that most study authors do not 
report characteristics of participants stratified by DR-TB but rather report on characteristics of 
all participants in the study as a whole.  
 
This review covered a period of 10 years during which major changes regarding XDR-TB 
diagnosis, given new-generation diagnostic tools, were introduced. These changes are 
expected to have had an influence on XDR-TB prevalence. This review included few studies;  
thus, it is possible that the calculated pooled prevalence estimate of XDR-TB in Africa could 
be an underestimation of the true prevalence of XDR-TB in Africa. This review only 
considered articles published in English potentially increasing the possibility of publication 
bias potentially causing an overestimation of the calculated pooled estimate of XDR-TB in 
Africa. To our knowledge, this is the first study to review the prevalence of pulmonary XDR-
TB amongst adults in Africa. 
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5.CONCLUSIONS  
5.1. Implications for practice 
 
This systematic reviews’ results show that the prevalence of XDR-TB is high in participants 
with MDR-TB. Thus, it would be advisable for mandatory second-line anti-TB DST to be 
done in all patients diagnosed with MDR-TB at commencement 2 
of treatment. This will allow for the early detection and treatment of XDR-TB. Although 
there is limited data on the factors associated with XDR-TB prevalence, patients receiving 
treatment for DR-TB who present with HIV infection and history of previous TB treatment 
must be assessed for XDR-TB infection as these are factors are associated with XDR-TB. 
The assessment of these patients is to allow for the diagnosis and treatment of XDR-TB thus 
potentially resulting in the reduction of XDR-TB burden in Africa. Due to the high 
heterogeneity among studies included in this systematic review and meta-analysis, the 
estimated prevalence of XDR-TB in Africa should be used with caution when developing 
healthcare policy.  
 
5.2. Implications for research 
 
We observed that some authors do not report on all demographic information regarding study 
participants. It would be advantageous if study authors report all demographic information 
about the study participants and the proportion of XDR-TB cases in comparison to DR-TB and 
MDR-TB cases.  Such information is paramount for health research, including systematic 
reviews, not only as a reliable reflection of the burden of XDR-TB disease in Africa but more 
so to work towards End TB in Africa by 2035. Since this review found limited information 
about factors associated with the prevalence of XDR-TB in Africa since only two of the 
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included studies reported on these factors. A systematic review and meta-analysis about factors 
associated with pulmonary XDR-TB amongst adults in Africa is needed.  
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PART D: APPENDIX CONTENTS 
APPENDIX 1: African Search Filter 
 
 
Africa OR African OR Algeria  OR Angola OR Benin OR Botswana OR Burkina Faso OR Burundi OR 
Cameroon OR Canary Islands OR Cape Verde OR Central African Republic OR Chad OR Comoros OR 
Congo OR Democratic Republic of Congo OR Djibouti OR Egypt OR Eritrea OR Ethiopia OR Gabon OR 
Gambia OR Ghana OR Guinea OR Ivory Coast OR “Cote d'Ivoire” OR Jamahiriya OR Kenya OR Lesotho 
OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR 
Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR 
“Sao Tome” OR Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR  St Helena OR Sudan OR 
Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR “Western Sahara” OR Zaire OR Zambia OR 
Zimbabwe  
 
*the search was done using text word fields 
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APPENDIX 2: Search strategy  
*strategy developed in MEDLINE 
#1 Tuberculosis, Multidrug-Resistant [MeSH] 
OR XDR Tuberculosis  
OR MDR tuberculosis  
OR  Multi-Drug Resistant Tuberculosis  
OR Drug-Resistant Tuberculosis  
OR Multidrug-Resistant Tuberculosis  
OR Extensively Drug Resistant Tuberculosis  
OR XDR TB  
OR MDR TB  
OR Mycobacterium tuberculosis  
#2 Prevalence [MeSH] 
OR prevalence  
OR proportion  
OR rate  
OR statistic  
OR epidemiology  
OR epidemiological  
OR frequency  
#3 Africa search filters (see Appendix 2) 
#4 #1 AND #2 AND #3 (for prevalence of XDR-TB in Africa) 
#5 Risk Factors [MeSH] 
OR Risk  
OR associated  
OR association  
OR associations  
OR predict  
OR prediction  
OR predictors  
OR probability  
OR odds ratios  
OR correlation  
OR determinant 
#6 #1 AND #3 AND #5 (represents risk predictors of XDR-TB in Africa) 
*strategy can be modified for use in different electronic databases. 
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APPENDIX 3: Data extraction form 
1. General Information 
Study ID (e.g Kosmas, 2018)  
Reviewers details   
Review date (dd/mm/yyyy)  
Study title  
Study author(s)  
Year of publication  
Article Citation  
Publication type  Abstract Yes No 
Scientific paper Yes No 
Full report (Country generated) Yes No 
Grey literature Yes No 
Thesis (Master / PhD) Yes No 
Other (specify):   
 
 
Articles referenced to follow up  
 
 
 
Authors contact details Email address: 
Telephone number:  
Notes 
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2. Study eligibility  
 Eligibility criteria Specify Eligibility 
criteria met 
Location 
in text 
 Study included the following   (Yes/No/ 
Unclear/ 
Not applicable) 
 (page #) 
Study setting  Country in Africa  
(see protocol for list of African countries) 
   
Study design  
(see protocol for 
list of eligible 
study design) 
Observational study Yes No   
Population-based study  Yes No   
Cross-sectional surveys  Yes No   
Baseline cohort studies data  Yes No   
Baseline cases control study data Yes No   
Baseline experimental study data  Yes No   
Other study design: (specify)   
Condition of 
interest  
Pulmonary XDR-TB Yes No   
Publication date Was the article published within the review 
period (01/01/2006-31/07/2018)? 
Yes No   
Age Adults only Yes No   
Adults and children Yes No   
Adult and children studies: results 
differentiate children <15? 
Yes No   
Diagnostic test  Based on any WHO recommended laboratory 
procedures? 
Yes No   
Case definition  
 
Generic XDR-TB definition? Yes No   
TB Population 
 
Only XDR-TB population  Yes No   
Type of outcome 
measure  
Outcome reported Prevalence   
Other (specify):    
Ethical approval Authors’ state ethical approval obtained? Yes No   
Decision 
regarding study 
Reasoning for inclusion: 
Reasoning for exclusion: 
Notes 
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3. Study characteristic  
 Descriptions as reported in paper Location in text 
(page #) 
Study objective   
Country of study     
Study design Observational study Yes No  
 Population-based study  Yes No  
 Cross-sectional surveys  Yes No  
 Baseline cohort studies data  Yes No  
 Baseline cases control study data Yes No  
 Baseline experimental study data  Yes No  
 Other study design: (specify) 
 
 
 
Sampling method   
Study start date   
Study end date    
Study period (duration of 
study e.g. 1 yr) 
  
Data sources   
Notes  
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4. Participants characteristics 
 Descriptions as reported in paper Location in text 
(page #) 
Population description    
Inclusion criteria  
 
 
Exclusion criteria  
 
 
Site of recruitment of 
participants  
Clinic Yes No  
Hospital Yes No  
Community Yes No  
Other (specify): 
 
 
Age  Mean/median    
Range   
15-29 Number %  
30-45 Number %  
46-60 Number %  
61-75 Number %  
>75 Number %  
Gender  Male Number %  
Female Number %  
Notes 
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5. Outcomes and Results 
Outcome 1: XDR-TB Prevalence  
Outcome 1: Prevalence Description as reported in paper Location in text 
(page # ) 
Total cohort included studied   
No of cohort diagnosed with TB   
No of cohort diagnosed with DS-TB   
No of cohort diagnosed with DR-TB   
No diagnosed with MDR-TB   
No of XDR-TB    
No of XDR in cohort compared to TB DR-TB MDR-TB  
   
% of XDR in cohorts     
XDR in cohorts (95% confidence intervals)     
Notes  
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Outcome 2: Factors associated with the prevalence of XDR-TB in Africa 
Factors / variable 
 
Total  
 
Value 
(% ) 
Location in text 
 (page #) 
HIV status Positive    
Negative    
Unknown    
History of previous TB 
treatment  
Yes    
No    
Unknown    
Previous TB treatment 
status 
Cured    
Treatment completed    
Default    
Failure    
Transferred out    
Hospitalization history  Previous year     
Never hospitalised    
CD4 count (cell/ ms2) <200 cell/ms2    
>200 cell/ms2    
Mean CD4 count    
Weight (kg) <50kg     
>50kg     
Mean weight    
Smoking status Yes    
No    
Unknown    
Diabetic Yes    
No    
Unknown    
Age Mean/ median    
 Range     
Gender Male     
 female    
Other      
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6. Other information 
 Description as reported in paper Location in text 
(page #) 
Limitations of article   
 
 
 
 
 
 
 
 
 
 
 
 
Study funding sources 
(including funders 
influence) 
  
Possible conflicts of 
interests  
(for study authors) 
 
 
 
 
Notes 
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APPENDIX 4: PRISMA 2009 Checklist  
Section/topic   #  Checklist item   
Reported 
on page 
#   
TITLE       
Title   1  Identify the report as a systematic review, meta-analysis, or both.     
ABSTRACT       
Structured 
summary   
2  Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number.   
  
INTRODUCTION      
Rationale   3  Describe the rationale for the review in the context of what is already 
known.   
  
Objectives   4  Provide an explicit statement of questions being addressed with reference 
to participants, interventions, comparisons, outcomes, and study design 
(PICOS).   
  
METHODS       
Protocol and 
registration   
5  Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information including 
registration number.   
  
Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used 
as criteria for eligibility, giving rationale.   
  
Information 
sources   
7  Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.   
  
Search   8  Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.   
  
Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included 
in systematic review, and, if applicable, included in the meta-analysis).   
  
Data collection 
process   
10  Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.   
  
Data items   11  List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.   
  
Risk of bias in 
individual studies   
12  Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.   
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Summary 
measures   
13  State the principal summary measures (e.g., risk ratio, difference in 
means).   
  
Synthesis of 
results   
14  Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.   
  
 
Section/topic   #  Checklist item   
Reported on 
page #   
Risk of bias across 
studies   
15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).   
  
Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.   
  
RESULTS       
Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.   
  
Study characteristics   18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.   
  
Risk of bias within 
studies   
19  Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).   
  
Results of individual 
studies   
20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.   
  
Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.   
  
Risk of bias across 
studies   
22  Present results of any assessment of risk of bias across studies (see Item 15).     
Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).   
  
DISCUSSION       
Summary of evidence   24  Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).   
  
Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).   
  
Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.   
  
FUNDING       
Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.   
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APPENDIX 5: PLOS ONE instruction to authors 
 
Submission Guidelines for PLOS ONE journal 
Length Manuscripts can be any length. There are no restrictions 
on word count, number of figures, or amount of supporting 
information. 
  
We encourage you to present and discuss your findings 
concisely. 
Font Use a standard font size and any standard font, except for 
the font named “Symbol”. To add symbols to the 
manuscript, use the Insert → Symbol function in your 
word processor or paste in the appropriate Unicode 
character. 
Headings Limit manuscript sections and sub-sections to 3 heading 
levels. Make sure heading levels are clearly indicated in 
the manuscript text. 
Layout and 
spacing 
Manuscript text should be double-spaced. 
Do not format text in multiple columns. 
Page and line 
numbers 
Include page numbers and line numbers in the manuscript 
file. Use continuous line numbers (do not restart the 
numbering on each page). 
Footnotes Footnotes are not permitted. If your manuscript contains 
footnotes, move the information into the main text or the 
reference list, depending on the content. 
Language Manuscripts must be submitted in English.  
You may submit translations of the manuscript or abstract 
as supporting information. Read the supporting 
information guidelines. 
Abbreviations Define abbreviations upon first appearance in the text. 
Do not use non-standard abbreviations unless they appear 
at least three times in the text. 
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Keep abbreviations to a minimum. 
Reference PLOS uses “Vancouver” style, as outlined in the ICMJE 
sample references 
 
 
 
Manuscript Organization 
Manuscripts should be organized as follows. Instructions for each element appear below the 
list. 
 
Beginning section: The following elements are required in the following order: 
➢ Title page: List title, authors, and affiliations as first page of manuscript 
➢ Abstract 
➢ Introduction 
 
 Middle section: The following elements can be renamed as needed and presented in 
any order: 
➢ Materials and Methods 
➢ Results 
➢ Discussion 
➢ Conclusions (optional) 
 
 Ending section: The following elements are required, in order: 
➢ Acknowledgments 
➢ References 
➢ Supporting information captions (if applicable) 
 
Other elements 
➢ Figure captions are inserted immediately after the first paragraph in which the figure 
is cited. 
➢ Figure files are uploaded separately. 
➢ Tables are inserted immediately after the first paragraph in which they are cited. 
➢ Supporting information files are uploaded separately. 
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Systematic reviews and meta-analyses 
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly 
formulated question that uses explicit, systematic methods to identify, select, and critically 
appraise relevant research, and to collect and analyze data from the studies that are included in 
the review. These reviews differ substantially from narrative-based reviews or synthesis 
articles. Statistical methods (meta-analysis) may or may not be used to analyze and summarize 
the results of the included studies. 
Reports of systematic reviews and meta-analyses must include a completed PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow 
diagram to accompany the main text.  
Authors must also state in their “Methods” section whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information and 
provide the registry number in the abstract. 
If your article is a systematic review or a meta-analysis you should: 
➢ State this in your cover letter 
➢ Select “Research Article” as your article type when submitting 
➢ Include the PRISMA flow diagram as Fig 1 (required where applicable) 
➢ Include the PRISMA checklist as supporting information 
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